RGNX — REGENXBIO Inc. Stock Price, Chart & AI Report

Negative Mar 2, 2026 • 00:04 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

A securities class action lawsuit has been filed against REGENXBIO, Inc. for allegedly providing materially false and misleading statements regarding the efficacy and safety of its RGX-111 gene therapy trial for Hurler syndrome. Investors who purchased REGENXBIO securities between February 9, 2022 and January 27, 2026 may be entitled to compensation. The deadline to serve as lead plaintiff is April 14, 2026.

RGNX securities class action REGENXBIO RGX-111 gene therapy Hurler syndrome false statements investor compensation

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misrepresentations and concealment of adverse facts regarding the safety and efficacy of its RGX-111 clinical trial, resulting in investor damages.

Negative Feb 26, 2026 • 23:36 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire announces class action lawsuits against PayPal and REGENXBIO. PayPal faces allegations of providing false revenue projections and growth targets that proved unachievable, leading to a 20% stock decline after disappointing Q4 2025 results and CEO transition. REGENXBIO is sued over concealed safety concerns regarding its RGX-111 gene therapy, which experienced a 17.8% stock drop after the FDA placed a clinical hold due to a tumor found in a trial participant.

PYPL RGNX class action lawsuit securities fraud false guidance stock decline FDA clinical hold gene therapy

Sentiment note

Company faces class action lawsuit for allegedly concealing material adverse facts about safety and efficacy of RGX-111 gene therapy. FDA placed clinical hold on the drug after a tumor was found in a trial participant, causing stock to decline 17.8% in a single day.

Negative Feb 26, 2026 • 21:57 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

A securities class action lawsuit has been filed against REGENXBIO, Inc. for allegedly providing misleading statements about its RGX-111 gene therapy candidate while concealing material adverse facts concerning efficacy and safety. Investors who purchased securities between February 9, 2022 and January 27, 2026 may be eligible for compensation, with an April 14, 2026 deadline to serve as lead plaintiff.

RGNX securities class action REGENXBIO RGX-111 gene therapy Hurler syndrome misleading statements investor compensation

Sentiment note

The company is the subject of a securities class action lawsuit alleging it made false and misleading statements about its RGX-111 trial while concealing material adverse facts regarding efficacy and safety, resulting in investor damages.

Negative Feb 23, 2026 • 18:44 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

Rosen Law Firm has filed a class action lawsuit against REGENXBIO, Inc. on behalf of investors who purchased securities between February 9, 2022 and January 27, 2026. The lawsuit alleges that defendants made false and misleading statements regarding the efficacy and safety of RGX-111, a gene therapy candidate for Hurler syndrome, while concealing material adverse facts about the trial study. Investors who purchased during this period may be entitled to compensation. The deadline to serve as lead plaintiff is April 14, 2026.

RGNX class action lawsuit securities fraud RGX-111 gene therapy material misstatement investor compensation

Sentiment note

The company is the subject of a securities class action lawsuit alleging that defendants made false and misleading statements about the efficacy and safety of their lead product candidate RGX-111 while concealing material adverse facts. This indicates serious allegations of investor fraud and potential financial liability.

Negative Feb 23, 2026 • 17:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against REGENXBIO Inc. alleging that the company made materially false and misleading statements regarding its gene therapy RGX-111 for treating Mucopolysaccharidosis Type I. The complaint claims defendants overstated the efficacy and safety profile of the treatment and lacked reasonable basis for positive statements about clinical trial results. Investors who purchased REGENXBIO securities between February 9, 2022 and January 27, 2026 may be eligible to join the lawsuit, with a lead plaintiff deadline of April 14, 2026.

RGNX class action lawsuit securities fraud gene therapy RGX-111 Mucopolysaccharidosis Type I clinical trial investor harm

Sentiment note

The company is the subject of a securities fraud class action lawsuit alleging materially false and misleading statements about its gene therapy product RGX-111, including overstated efficacy and safety profiles and lack of reasonable basis for positive clinical trial claims.

Negative Feb 20, 2026 • 23:47 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

Rosen Law Firm has filed a class action lawsuit against REGENXBIO, Inc. on behalf of investors who purchased securities between February 9, 2022 and January 27, 2026. The lawsuit alleges that defendants made false and misleading statements about the efficacy and safety of RGX-111, a gene therapy candidate for Hurler syndrome, while concealing material adverse facts about the trial. Investors who wish to serve as lead plaintiff must file by April 14, 2026.

RGNX class action lawsuit securities fraud gene therapy RGX-111 Hurler syndrome misleading statements investor compensation

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misrepresentations and concealment of adverse facts regarding clinical trial data for its lead product candidate RGX-111, resulting in investor losses.

Negative Feb 20, 2026 • 19:51 UTC GlobeNewswire Inc. • The Schall Law Firm

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors to join a class action lawsuit against REGENXBIO Inc. for securities fraud. The company allegedly made false and misleading statements about its product candidate RGX-111, concealing negative efficacy and safety data while presenting overwhelmingly positive statements. The fraud was revealed when an intraventricular CNS tumor was discovered in a study participant, causing investor losses.

RGNX securities fraud class action lawsuit RGX-111 false statements CNS tumor investor losses Securities Exchange Act

Sentiment note

The company is accused of making false and misleading statements about product candidate RGX-111, concealing negative safety and efficacy data. The discovery of an intraventricular CNS tumor in a study participant and subsequent investor losses indicate serious regulatory and reputational damage.

Negative Feb 19, 2026 • 17:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against REGENXBIO Inc. alleging that the company made materially false and misleading statements regarding its RGX-111 gene therapy development and clinical trial results. The lawsuit covers investors who purchased REGENXBIO securities between February 9, 2022 and January 27, 2026. The lead plaintiff deadline is April 14, 2026.

RGNX class action lawsuit securities fraud REGENXBIO RGX-111 gene therapy clinical trial investor harm

Sentiment note

The company is the subject of a securities fraud class action lawsuit alleging materially false and misleading statements about its RGX-111 gene therapy, overstated efficacy and safety profiles, and lack of reasonable basis for positive clinical trial claims. This represents significant legal and reputational risk to investors.

Negative Feb 18, 2026 • 22:00 UTC GlobeNewswire Inc. • The Gross Law Firm

Shareholders that lost money on REGENXBIO Inc.(RGNX) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

The Gross Law Firm has initiated a class action lawsuit against REGENXBIO Inc. (RGNX) on behalf of shareholders who purchased shares between February 9, 2022 and January 27, 2026. The lawsuit alleges that defendants made false and misleading statements about the efficacy and safety of RGX-111, a gene therapy for Hurler syndrome, while concealing material adverse facts. On January 28, 2026, the FDA placed a clinical hold on RGX-111 after an intraventricular CNS tumor was discovered in a trial participant, causing RGNX stock to plummet 17.8% in a single day from $13.41 to $11.01 per share.

RGNX class action lawsuit securities fraud gene therapy FDA clinical hold RGX-111 Hurler syndrome material misstatement

Sentiment note

The company faces a class action lawsuit alleging material misstatements and concealment of safety data regarding its lead product RGX-111. An FDA clinical hold was placed on the therapy following discovery of a CNS tumor in a trial participant, resulting in a significant 17.8% single-day stock price decline. These developments indicate serious regulatory, legal, and commercial risks.

Negative Feb 17, 2026 • 19:44 UTC GlobeNewswire Inc. • Faruqi & Faruqi, Llp

RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026

A securities class action has been filed against REGENXBIO Inc. for allegedly making false and misleading statements regarding the efficacy and safety of its RGX-111 gene therapy trial. The FDA placed a clinical hold on RGX-111 and RGX-121 following a case of a CNS tumor in a trial participant, causing the stock to fall 17.9% on January 28, 2026. Investors have until April 14, 2026 to seek lead plaintiff status.

RGNX securities class action clinical hold gene therapy FDA RGX-111 RGX-121 MPS I

Sentiment note

The company faces a federal securities class action lawsuit alleging false and misleading statements about drug trial safety and efficacy. The FDA placed clinical holds on two key investigational therapies following a serious adverse event (CNS tumor), resulting in a 17.9% stock price decline. This represents significant regulatory, legal, and financial headwinds.

Negative Feb 17, 2026 • 17:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against REGENXBIO Inc. alleging that the company made materially false and misleading statements regarding its RGX-111 gene therapy development and clinical trial results. The lawsuit covers investors who purchased REGENXBIO securities between February 9, 2022 and January 27, 2026. Investors have until April 14, 2026 to request lead plaintiff status.

RGNX class action lawsuit securities fraud REGENXBIO RGX-111 gene therapy clinical trial investor harm

Sentiment note

The company is the subject of a securities fraud class action lawsuit alleging materially false and misleading statements about its RGX-111 gene therapy, overstated efficacy and safety profiles, and lack of reasonable basis for positive clinical trial claims. This represents significant legal and reputational risk to investors.

Negative Feb 17, 2026 • 12:30 UTC Benzinga • Business Wire

REGENXBIO Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – RGNX

REGENXBIO Inc. (NASDAQ: RGNX) faces a class action lawsuit for securities violations. The company allegedly made false and misleading statements about the safety and efficacy of its RGX-111 product candidate while concealing adverse information from investors. The FDA placed a clinical hold on RGX-111 after a clinical trial participant developed a tumor.

RGNX securities fraud class action lawsuit RGX-111 FDA clinical hold adverse events investor protection

Sentiment note

The company is facing a securities class action lawsuit for making false and misleading statements about drug safety and efficacy while concealing adverse information. An FDA clinical hold on a key product candidate due to a tumor development in a trial participant represents a significant setback and regulatory concern.